Crotamiton

Identification

Summary

Crotamiton is a topical scabicidal and antipruritic agent used for scabies eradication and for the relief of pruritus.

Brand Names
Crotan, Eurax
Generic Name
Crotamiton
DrugBank Accession Number
DB00265
Background

Crotamiton is a scabicidal and antipruritic agent available as a cream or lotion for topical use only. It is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 203.2802
Monoisotopic: 203.131014171
Chemical Formula
C13H17NO
Synonyms
  • Crotamiton

Pharmacology

Indication

For eradication of scabies (Sarcoptes scabiei) and for symptomatic treatment of pruritic skin.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofPruritis of the skin••••••••••••
Treatment ofScabies••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Crotamiton is usually used to treat pruritis (itching of the skin) caused by scabies or sunburn. Crotamiton relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching. Due to this cooling effect it is also effective for the relief of sunburn. The drug is also believed to kill scabies through an unknown mechanism.

Mechanism of action

Crotamiton is an antiparasitic that is toxic to the scabies mite. Crotamiton also relieves itching by producing what is called a counter-irritation. As crotamiton evaporates from the skin, it produces a cooling effect. This cooling effect helps to divert your body's attention away from the itching.

Absorption

10 % absorbed when applied locally.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
No interactions found.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Crotamitex (Gepepharm) / Euracin (Green Cross (South Korea))
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
EuraxCream100 mg/1gTopicalSun Pharmaceutical Industries, Inc.2008-12-152018-02-28US flag
EuraxLotion100 mg/1gTopicalBristol Myers Squibb Pharma Company2009-06-012009-10-31US flag
EuraxLotion100 mg/1gTopicalSun Pharmaceutical Industries, Inc.2008-11-132018-04-30US flag
EuraxCream100 mg/1gTopicalBristol Myers Squibb Pharma Company2009-01-012009-02-28US flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
CrotanLotion100 mg/1gTopicalMarnel Pharmaceuticals, Inc.2022-01-15Not applicableUS flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
A-Bite CreamCreamTopicalHOE PHARMACEUTICALS SDN. BHD.2020-09-08Not applicableMalaysia flag
CROTAMITON CREAM 10% v/wCream10 % v/wTopicalSUNWARD PHARMACEUTICAL PRIVATE LIMITED1990-06-18Not applicableSingapore flag
CROTAMITON LOTION 10% v/vLotion10 % v/vTopicalSUNWARD PHARMACEUTICAL PRIVATE LIMITED1990-07-17Not applicableSingapore flag
Crotamiton Lotion 10% w/wLotion10 % w/wTopicalSM PHARMACEUTICALS SDN. BHD.2020-09-08Not applicableMalaysia flag
CROTOCORT CREAM 10% W/WCream10 % W/WTopicalSM PHARMACEUTICALS SDN. BHD.2020-09-08Not applicableMalaysia flag

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Anilides
Direct Parent
Anilides
Alternative Parents
Toluenes / Tertiary carboxylic acid amides / Organopnictogen compounds / Organonitrogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Anilide / Aromatic homomonocyclic compound / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Hydrocarbon derivative / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
enamide (CHEBI:31439)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
2EEH27851Y
CAS number
483-63-6
InChI Key
DNTGGZPQPQTDQF-XBXARRHUSA-N
InChI
InChI=1S/C13H17NO/c1-4-8-13(15)14(5-2)12-10-7-6-9-11(12)3/h4,6-10H,5H2,1-3H3/b8-4+
IUPAC Name
N-ethyl-N-(2-methylphenyl)but-2-enamide
SMILES
CCN(C(=O)C=CC)C1=CC=CC=C1C

References

General References
  1. Buffet M, Dupin N: Current treatments for scabies. Fundam Clin Pharmacol. 2003 Apr;17(2):217-25. [Article]
  2. FDA Approved Drug Products: Eurax (crotamiton) topical [Link]
KEGG Drug
D01381
PubChem Compound
2883
PubChem Substance
46508599
ChemSpider
599515
BindingDB
50240091
RxNav
21766
ChEMBL
CHEMBL1200709
ZINC
ZINC000000056427
PharmGKB
PA164745460
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Crotamiton
FDA label
Download (143 KB)
MSDS
Download (57 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
  • Ranbaxy laboratories inc
  • Summers laboratories inc
Packagers
  • Contract Pharm
  • Pharmedix
  • Ranbaxy Laboratories
Dosage Forms
FormRouteStrength
CreamCutaneous10.000 g
SolutionTopical10 g
CreamTopical10 % v/w
CreamTopical10 g
LotionTopical10 % v/v
LotionTopical10 % w/w
CreamTopical
LotionTopical10 %
EmulsionTopical10 g
CreamTopical
CreamTopical100 mg/1g
LotionTopical100 mg/1g
CreamTopical10 %
CreamTopical10 g/100g
LotionTopical9.65 g
CreamTopical10 % w/w
LotionTopical10 g
LotionTopical
Prices
Unit descriptionCostUnit
Eurax 10% Lotion 454 gm Bottle353.03USD bottle
Eurax 10% Lotion 60 gm Bottle54.21USD bottle
Eurax 10% Cream 60 gm Tube51.99USD tube
Eurax 10% cream0.27USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
boiling point (°C)154 °C at 1.30E+01 mm HgPhysProp
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.353 mg/mLALOGPS
logP2.7ALOGPS
logP3.09Chemaxon
logS-2.8ALOGPS
pKa (Strongest Basic)-0.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area20.31 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity64.15 m3·mol-1Chemaxon
Polarizability23.07 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9905
Blood Brain Barrier+0.9939
Caco-2 permeable+0.8303
P-glycoprotein substrateNon-substrate0.788
P-glycoprotein inhibitor INon-inhibitor0.8611
P-glycoprotein inhibitor IINon-inhibitor0.709
Renal organic cation transporterNon-inhibitor0.8494
CYP450 2C9 substrateNon-substrate0.7767
CYP450 2D6 substrateNon-substrate0.6383
CYP450 3A4 substrateSubstrate0.586
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9461
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7792
Ames testNon AMES toxic0.7386
CarcinogenicityCarcinogens 0.5946
BiodegradationNot ready biodegradable0.9764
Rat acute toxicity2.1007 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9726
hERG inhibition (predictor II)Non-inhibitor0.8168
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (9.18 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-01bl-5900000000-f2f8a0d107e489eb71dd
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0090000000-70e1ca34f13b9e4b9599
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-1190000000-02218095d009d51f0b72
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-9850000000-24da05acdd172bfde5f5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9700000000-ae61a473efc6d72b8781
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9600000000-6aaa881b4c06e68ed133
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-9500000000-27cbd5bf3c121b56d6cc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066u-9400000000-12ca412deed8c16a0f22
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066u-9300000000-427f77529d09e1395f78
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-066u-9200000000-a03907e2130c0b4a1530
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0960000000-1e54c7d036ee5fb85d0c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0udi-4090000000-c36f2f54bcfc81ba21ce
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-000f-5920000000-6650b12845bcd005932c
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-1900000000-2de2e0d533935466d6ab
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-9300000000-2654e6580cbbb815ab06
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0536-5900000000-9834d4e4d288a60b3cd2
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 13, 2005 13:24 / Updated at January 02, 2024 23:44